Viking Therapeutics Announces $200M Common Stock And $200M Convertible Senior Notes Due 2032; Proceeds To Fund VK2735, VK3019 Clinical Development And General Corporate Purposes
Viking Therapeutics, Inc. (NASDAQ:VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its intention to offer, subject to
Viking Therapeutics is raising $400 million total to pay for drug testing. This shows the company believes in its medicine ideas and has money to keep going.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.